TCMBANKIN003075 |
zederone |
CHEBI:80915; 7727-79-9; AKOS032948437; C17085; Zederone |
C15H18O3 |
246.3 g/mol |
CC1=CCCC2(C(O2)C(=O)C3=C(C1)OC=C3C)C |
TCMBANKIN004014 |
lutein-3-linolenate |
|
C58H84O3 |
|
CCC=CCC=CCC=CCCCCCCCC(=O)OC1CC(=C(C(C1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2C(=CC(CC2(C)C)O)C)C)C)C |
TCMBANKIN006280 |
biopterin |
|
C9H11N5O3 |
237.22 |
CC(C(C1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O |
TCMBANKIN010162 |
isoxanthopterin-6-carboxylic acid |
isoxanthopterin-6-carboxylicacid |
C7H5N5O4 |
0 |
C12=C(NC(=O)C(=N1)C(=O)O)NC(=NC2=O)N |
TCMBANKIN011066 |
astaxanthin |
3,3'-dihydroxy-4,4'-diketo-beta,beta-carotene |
C40H52O4 |
596.8 g/mol |
CC1=C(C(CC(C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C |
TCMBANKIN011483 |
jacaranone |
|
C9H10O4 |
182.17 g/mol |
COC(=O)CC1(C=CC(=O)C=C1)O |
TCMBANKIN016334 |
(-)-noradrenaline |
to_000024; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; KBio3_001579; CHEBI:18357; NCGC00159406-02; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Levoarterenol; KBio2_006625; KBio1_000230; L-Noradrenaline; NCGC00159406-05; Nor adrenalin (TN); Nor adrenalin; Noradrenaline (JP15); NINDS_000230; 4-[(1R)-2-amino-1-hydroxy-ethyl]pyrocatechol; Spectrum_001009; norepinephrinum; SPECTRUM1500436; KBio2_004057; Spectrum3_000520; KBio2_001489; DivK1c_000230; nchembio705-1; PDSP1_001111; 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol; 51-41-2; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; KBioSS_001489; C00547; NCGC00159406-04; BSPBio_002079; AIDS335520; A7257_SIGMA; KBioGR_000635; D00076; (−)-Norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; Spectrum5_001068; Arterenol; Spectrum4_000078; PDSP2_001095; Spectrum2_001064; (-)-(R)-Norepinephrine; SGCUT00123; AIDS-335520; Norepinephrine (INN); SPBio_001048; IDI1_000230 |
C8H11NO3 |
169.18 |
C1=CC(=C(C=C1C(CN)O)O)O |
TCMBANKIN018631 |
Izalpinin |
Isalpinin; 3,5-dihydroxy-7-methoxy-2-phenyl-chromen-4-one; 3,5-dihydroxy-7-methoxy-2-phenylchromen-4-one; izalpinin; 4H-1-Benzopyran-4-one, 3,5-dihydroxy-7-methoxy-2-phenyl-; 3,5-dihydroxy-7-methoxy-2-phenyl-chromone; 480-14-8; 3,5-dihydroxy-7-methoxy-2-phenyl-4-chromenone |
C16H12O5 |
284.26 |
COC1=CC(=C2C(=C1)OC(=C(C2=O)O)C3=CC=CC=C3)O |
TCMBANKIN020836 |
xanthopterin |
2-amino 4,6 pteridinedione |
C6H5N5O2 |
179.14 g/mol |
C1=NC2=C(C(=O)NC(=N2)N)NC1=O |
TCMBANKIN020845 |
7-hydroxybiopterin |
|
C9H11N5O4 |
0 |
CC(C(C1=NC2=C(NC1=O)NC(=NC2=O)N)O)O |
TCMBANKIN022518 |
noradrenaline |
l-Norepinephrine bitartrate; 33404-26-1; l-Arterenol d-bitartrate; Norepinephrine hydrogen tartrate; 350-25-4; Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)-, tartrate (1:1) (salt); API0007150; 1,2-Benzenediol, 4-((1R)-2-amino-1-hydroxyethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt); 341N180; L(+)-TARTARIC ACID; NOREPINEPHRINE; Noradrenalin bitartrate, l-; Arterenol bitartrate; Noradrenaline acid tartrate; MolPort-029-943-999; Norartrinal bitartrate; Levarterenol; ZW81GF408B; Norepinephrine bitartrate anhydrous; L-Noradrenaline bitartrate; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol (L-(+))-bitartrate salt; AKOS007930222; Noradrenaline, tartrate (1:1); Norepinephrine tartrate; 73-98-3; Noradrenaline bitartrate; Noradrenaline tartrate; l-Noradrenaline tartrate; UNII-ZW81GF408B; C8H11NO3.C4H6O6; (-)-Norepinephrine bitartrate; (-)-Noradrenaline (+)-bitartrate; BG01031160; 51-40-1; 2477-42-1; Levonorepinephrine; 2595AH; l-Noradrenaline d-bitartrate; Noradrenaline hydrogen tartrate; HMS2089E22; (-)-R-Norepinephrine bitartrate; NSC 169106; 51-41-2 (Parent); API0003624; norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); l-Arterenol bitartrate; Levarterenol bitartrate; Noradrenalin bitartrate; L-(-)-Noradrenaline (+)-bitartrate salt monohydrate; BENZYL ALCOHOL, alpha-(AMINOMETHYL)-3,4-DIHYDROXY-, (-)-, TARTRATE (1:1); 24868-01-7; 893-91-4; EINECS 200-095-0 |
C8H12NO3+ |
170.19 g/mol |
C1=CC(=C(C=C1C(C[NH3+])O)O)O |
TCMBANKIN023589 |
norarmepavine |
L-(-)-N-norarmepavine; ZINC24717722; SMR000156290; 4-[[(1S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]phenol; BDBM50292465; CHEMBL453038; AC1OE5L2; Norarmepavine; HMS2198P24; MLS000575014 |
C18H21NO3 |
299.4 g/mol |
COC1=C(C=C2C(NCCC2=C1)CC3=CC=C(C=C3)O)OC |
TCMBANKIN024466 |
7-hydroxy-3,6-bis(tigloyloxy)tropane |
|
C18H27NO5 |
337.4 g/mol |
CC=C(C)C(=O)OC1CC2C(C(C(C1)N2C)OC(=O)C(=CC)C)O |
TCMBANKIN024889 |
ranachrome 5 |
|
C7H5N5O3 |
207.15 g/mol |
C1=C(N=C2C(=O)NC(=NC2=N1)N)C(=O)O |
TCMBANKIN029144 |
adrenaline(i) |
|
C9H13NO3 |
|
CNCC(C1=CC(=C(C=C1)O)O)O |
TCMBANKIN030462 |
4-Keto Nonanal |
|
|
|
|
TCMBANKIN036465 |
randainal |
|
C18H16O3 |
280.32 |
C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)C=CC=O)O |
TCMBANKIN037648 |
Lutein |
SMP1_000317; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol; SCHEMBL10029505; CHEBI:28838; NSC59193; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-1-cyclohex-2-enol; C08601; LMPR01070274; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-2-en-1-ol; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-2-en-1-ol; lutein; 127-40-2; Xanthophyll; (3R,3'R,6'R)-beta,epsilon-carotene-3,3'-diol; BCBcMAP01_000190; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-1-cyclohex-2-enol |
C40H56O2 |
568.87 |
CC1=C(C(CC(C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2C(=CC(CC2(C)C)O)C)C)C |
TCMBANKIN042107 |
Adrenaline |
adrenaline |
|
219.66 g/mol |
|
TCMBANKIN043827 |
7-keto-i-pimara-8(14),15-dien-19-oic acid |
|
C20H28O3 |
316.435 |
CC1(CCC2C(=C1)C(=O)CC3C2(CCCC3(C)C(=O)O)C)C=C |
TCMBANKIN045421 |
canthin-6-one |
NSC 103003; MEGxp0_000046; canthin-6-one; 6H-Indolo(3,2,1-de)(1,5)naphthyridin-6-one; NCIOpen2_007333; AIDS228088; ACon0_001416; AIDS-228088; C09098; NSC103003; 479-43-6; 6H-Indolo[3,2,1-de][1,5]naphthyridin-6-one; ZINC00898052 |
C14H8N2O |
220.226 |
c1([H])c([H])c(c2c(c(nc([H])c2[H])C([H])=C([H])C3=O)n34)c4c([H])c1[H] |
TCMBANKIN050143 |
4,4'-Diketo-3-hydroxy-beta-carotene |
beta,beta-Carotene-4,4/'-dione, 3-hydroxy-; 3-Hydroxycanthaxanthin; beta-Carotene-4,4'-dione, 3-hydroxy-, all-trans-; Phenicoxanthin; 3-Hydroxy-beta,beta-carotene-4,4'-dione; SCHEMBL149807; 4418-72-8; beta,beta-Carotene-4,4'-dione, 3-hydroxy-; 4,4'-diketo-3-hydroxy-β-carotene; 3-Hydroxy-4,4'-diketo-beta-carotene; All-trans-adonirubin; 4,4'-Diketo-3-hydroxy-beta-carotene |
C40H52O3 |
580.8 g/mol |
[C@]1([H])(O[H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C(\C([H])=C([H])\C(\C([H])([H])[H])=C([H])/C([H])=C([H])\C(\C([H])([H])[H])=C([H])\C([H])=C([H])\C([H])=C(/C([H])([H])[H])\C([H])=C([H])\C([
H])=C(/C([H])([H])[H])\C([H])=C([H])\C2=C(C([H])([H])[H])C(=O)C([H])([H])C([H])([H])C2(C([H])([H])[H])C([H])([H])[H])=C(C([H])([H])[H])C1=O |
TCMBANKIN058017 |
3-Epizaluzanin C |
CHEBI:81375; AC1LAM4X; (3aS,6aR,8R,9aR,9bS)-8-hydroxy-3,6,9-trimethylidene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[5,4-d]furan-2-one; CHEMBL461700; AIDS070709; 67667-64-5; AIDS-070709; (3aS,6aR,8R,9aR,9bS)-8-hydroxy-3,6,9-trimethylidene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one; Isozaluzanin C; (3as,6ar,8r,9ar,9bs)-8-hydroxy-3,6,9-trimethylene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[5,4-d]furan-2-one; SCHEMBL17214374; (3aS,6aR,8R,9aR,9bS)-8-hydroxy-3,6,9-trimethylene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[5,4-d]furan-2-one; C17912; CTK7F2785; (3aS,6aR,8R,9aR,9bS)-8-hydroxy-3,6,9-trimethylene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one; 3-epizaluzanin c; Dehydrocostus lactone der.;zaluzain c;zaluzanin c;isozaluzanine |
C15H18O3 |
246.3 g/mol |
C=C1CCC2C(C3C1CC(C3=C)O)OC(=O)C2=C |
TCMBANKIN058459 |
Ranachrome 4 |
ZINC00901885; 2-Amino-4,7-dihydroxypteridine; 4,7(3H,8H)-Pteridinedione, 2-amino-; Isoxanthopterin; NCI60_000432; SpecPlus_000308; 2-Amino-4,7(3H,8H)-pteridinedione; 2-Amino-4,7-pteridinediol; Spectrum_000248; NSC 118090; NSC614991; 529-69-1; EU-0100712; 4,7(1H,8H)-Pteridinedione, 2-amino- (9CI); NCGC00015564-01; Lopac0_000712; 2-Aminopteridine-4,7-diol; NSC118090; DivK1c_006404; C03975; 2-amino-1,8-dihydropteridine-4,7-quinone; KBio2_003296; 2-amino-1,8-dihydropteridine-4,7-dione; KBio1_001348; 2-Amino-4,7-dihydroxy-1,3,5,8-tetraazanaphthalene; Lopac-I-7388; I7388_SIGMA; CHEBI:16713; 2-AMINO-4,7(1H,8H)-PTERIDINEDIONE; Spectrum4_001242; KBioSS_000728; KBio2_000728; KBio2_005864; 4,7(1H,8H)-Pteridinedione, 2-amino-; KBioGR_001764; EINECS 208-469-5; ST5451823; isoxanthopterin |
C6H5N5O2 |
179.14 g/mol |
C1=NC2=C(NC1=O)N=C(NC2=O)N |
TCMBANKIN059702 |
adonixanthin |
|
C40H54O3 |
582.9 g/mol |
CC1=C(C(CC(C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C |
TCMBANKIN059703 |
Zeaxanthin |
|
C40H56O2 |
568.87 |
CC1=C(C(CC(C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)O)C)C)C |
TCMBANKIN059719 |
canthaxanthin |
|
C40H52O2 |
564.8 g/mol |
CC1=C(C(CCC1=O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)CCC2(C)C)C)C)C |
TCMBANKIN061551 |
norarmepavine |
n-norarmepavine; L-(-)-N-norarmepavine; ZINC24717722; SMR000156290; 4-[[(1S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]phenol; BDBM50292465; CHEMBL453038; AC1OE5L2; Norarmepavine; HMS2198P24; MLS000575014 |
C18H21NO3 |
299.4 g/mol |
COC1=C(C=C2C(NCCC2=C1)CC3=CC=C(C=C3)O)OC |
TCMBANKIN061689 |
Uvadex |
DSSTox_GSID_20830; Methoxsalen plus ultraviolet radiation; 8-Methoxy-4',5',6,7-furocoumarin; NC00652; CC-30277; 9-Methoxy-7H-furo[3,2-g]chromen-7-one #; 9-Methoxyfuro(3,2-g)chromen-7-one; HMS2091D20; 4CN-0934; AK111265; 9-METHOXY-2H-FURO[3,2-G]CHROMEN-2-ONE; 9-methoxyfuro[3,2-g]chromen-7-one; Vitpso; NCGC00060938-02; U4VJ29L7BQ; SPBio_002557; 8-MOP; 8-Methoxy-4',6,7-furocoumarin; SDCCGMLS-0042377.P002; CPD000071170; Spectrum2_001052; s1952; NCGC00060938-03; Delta Brand of Methoxsalen; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; Methoxsalen, United States Pharmacopeia (USP) Reference Standard; Oxsoralen lotion; Oxsoralen; Dltasoralen; 8-Methoxy-6,7-furanocoumarin; Methoxsalen Canderm Brand; HMS2269P03; DSSTox_CID_830; NINDS_000763; KBioSS_001503; AB2000388; Methoxaten; EINECS 206-066-9; Meladinina; C01864; Methoxa-Dome; Oxoralen; Psoralen-mop; Xanthotoxin, analytical standard; NCGC00016418-04; CAS-298-81-7; KBio3_001497; AJ-39565; AN-12178; Methoxsalen [BAN:JAN]; NCGC00060938-05; 8-Methoxypsoralen, analytical standard; Dermatech Brand of Methoxsalen; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; NCGC00060938-04; NCGC00060938-06; CM-131; 8-Methoxyfuranocoumarin; Xanthotoxine; 12692-94-3; Prestwick0_000479; 8-Methoxy-2',6,7-furocoumarin; 5-Demethoxyisoimpinellin; Methoxy-8-psoralen; SMR000071170; SCHEMBL19168; MEGxp0_000095; LS-68; HSDB 2505; CS-1983; SC-13812; 9-methoxyfurano[3,2-g]chromen-2-one; NCGC00016418-03; ZINC2548959; Dermox; Psoralon-MOP; Canderm Brand of Methoxsalen; 8-methoxy-4'',5'':6,7-furocoumarin; 8MOP; Meladinin (VAN); 298M817; Oprea1_166319; NCGC00016418-14; OXSORALEN (TN); Meladinine; Oxsoralen Ultra; 7H-Furo[3, 9-methoxy-; Prestwick1_000479; AC-4259; BG00605120; Tox21_110432; BG0479; HMS3655B05; WLN: T C566 DO LVOJ BO1; Boehringer Ingelheim Brand of Methoxsalen; Uvadex; Puvamet; Sanofi Synthelabo Brand of Methoxsalen; Prestwick3_000479; NSC757114; Meladoxen; NCGC00016418-09; 5-19-06-00015 (Beilstein Handbook Reference); SAM002548974; 8-methoxyfurocoumarins; 8-methoxyfuranocoumarins; SR-01000629727-4; Oxsoralen-ultra; Q039; an 8-methoxyfurocoumarin; 8MO; methoxsalen; MFCD00005009; NCGC00178871-03; BSPBio_000618; Tox21_110432_1; MolPort-000-696-480; NCI-C55903; DSSTox_RID_75816; NCGC00016418-02; AB00052042_16; BRN 0196453; Xanthotoxin;Metoxaleno; Dltasoralen;Meladinine;Uvadex,;Oxsoralen; NCGC00016418-07; Zanthotoxin; BRD-K63430059-001-06-5; BDBM50041234; KBio2_004071; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); Methoxsalen Mex-America Brand; DB00553; Metoxaleno; 8-methoxy-[furano-3''.2'':6.7-coumarin]; NCGC00016418-10; 9-Methoxy-7H-furo[3,2- g][1]benzopyran-7-one; Spectrum_001023; Methoxa Dome; Methoxsalen (JP17/USP); 8-Methoxypsoralene; Methoxalen; EN300-52504; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; CHEBI:18358; HMS502G05; GP5578; I06-0695; MLS000062633; Tox21_302816; D08SKH; BC4157549; ICN Brand 1 of Methoxsalen; AB00052042-14; 8-methoxypsoralen; Proralone-mop; X0009; AC1L1HFY; Oxypsoralen; Methoxsalen Sanofi-Synthelabo Brand; FT-0602101; Q-100381; 9-Methoxypsoralen; ST24045871; Methoxsalen with ultra-violet A theraphy; NSC 45923; 8-Methoxy-(furano-3'.2':6.7-coumarin); Prestwick_661; 8-Methoxypsoralen with ultraviolet A therapy; Pharmakon1600-01500400; Sanofi-Synthelabo Brand of Methoxsalen; NCGC00016418-08; QXKHYNVANLEOEG-UHFFFAOYSA-N; FT-0082222; BRD-K63430059-001-03-2; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; xanthotoxin ; BPBio1_000680; Methoxsalen Delta Brand; Mex-America Brand of Methoxsalen; AX8020056; C-11618; KS-00000J91; STOCK1N-03091; NCGC00256435-01; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; Deltapsoralen; Oxsoralen Ul tra; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; IDI1_000763; D00139; Spectrum4_000052; SR-01000629727-2; Deltasoralen; CCRIS 2083; ICN Brand 3 of Methoxsalen; Meloxine; Prestwick2_000479; JC10026; J10204; 7-Furocoumarin; CHEMBL416; BSPBio_001997; Methoxsalen (JP15/USP); Geroxalen; 8-MOP ; Methoxsalen; KBio2_001503; NSC-757114; NSC45923; Ultramop; Methoxsalen Chinoin Brand; AM84906; 8-Methoxy-4',5':6,7-furocoumarin; Ammodin; Jsp005650; MCULE-2500932325; 8-MP; Methoxsalen [USP:BAN:JAN]; O-methylxanthotoxol; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; KBioGR_000543; DS-5159; UVADEX (TN); Methoxsalen, 8-; Methoxsalene; STK735539; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; Methoxsalen Dermatech Brand; 8-Methoxy-2',3',6,7-furocoumarin; NCGC00016418-05; NCGC00259316-01; DTXSID8020830; ACon1_000174; DB Brand of Methoxsalen; Tox21_201767; N1305; NCGC00178871-01; Ultra Mop; Puvalen; Methoxsalen (Oxsoralen); DivK1c_000763; Chinoin Brand of Methoxsalen; NSC-45923; Ammoidin; 8-Methoxypsoralen; NCGC00178871-02; SAM002564221; Meladinin; SR-01000629727; SBB005950; 8-Methoxy(furano-3'.2':6.7-coumarin); NCI60_004085; SBI-0051443.P003; SPBio_001004; NCGC00016418-12; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; XANTHOTOXIN; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; ICN Brand 2 of Methoxsalen; 8-Methoxy; SPECTRUM1500400; 8 Methoxypsoralen; HMS2096O20; HY-30151; 298-81-7; HMS3259L13; Spectrum5_001891; AKOS000277012; 8-methoxy-2'',3'',6,7-furocoumarin; AB00052042_17; 7H-Furo(3,2-G)(1)benzopyran-7-one, 9-methoxy-; UNII-U4VJ29L7BQ; NCGC00016418-11; MLS002303011; Z1258578369; AB00052042-15; Spectrum3_000499; Galderma Brand of Methoxsalen; BC204608; KBio2_006639; NCGC00016418-01; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; NCGC00016418-06; HMS1920N05; HMS1569O20; New-Meladinin; API0008254; Mex America Brand of Methoxsalen; 8-Methoxy-[furano-3'.2':6.7-coumarin]; NCGC00016418-15; KBio1_000763; BG01521511; A1783/0075596; CCG-36366; ST041029; Ultramop Lotion;8-methoxypsoralen;Methoxsalen plus ultraviolet radiation; 8-Methoxy-4',5',6,7-furocoumarin; 9-Methoxyfuro(3,2-g)chromen-7-one; Methoxsalen; NCGC00060938-02; 9-methoxyfuro[3,2-g]chromen-7-one; SDCCGMLS-0042377.P002; SPBio_002557; 8-MOP; Spectrum2_001052; NCGC00060938-03; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; Oxsoralen; 8-MOP Capsules; NINDS_000763; KBioSS_001503; EINECS 206-066-9; C01864; Methoxa-Dome; Oxoralen; CAS-298-81-7; KBio3_001497; Methoxsalen [BAN:JAN]; NCGC00060938-06; NCGC00060938-04; DRG-0088; 8-Methoxyfuranocoumarin; Prestwick0_000479; 12692-94-3; Xanthotoxine; Methoxy-8-psoralen; SMR000071170; MEGxp0_000095; HSDB 2505; Psoralon-MOP; Meladinin (VAN); Oprea1_166319; Meladinine; Oxsoralen Ultra; Prestwick1_000479; WLN: T C566 DO LVOJ BO1; Prestwick3_000479; Meladoxen; 5-19-06-00015 (Beilstein Handbook Reference); AIDS001590; 8MO; BSPBio_000618; NCI-C55903; BRN 0196453; KBio2_004071; ZINC00381730; Spectrum_001023; 8-Methoxypsoralene; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; Methoxalen; MLS000062633; Oxypsoralen; 9-Methoxypsoralen; Methoxsalen with ultra-violet A theraphy; NSC 45923; 8-Methoxy-(furano-3'.2':6.7-coumarin); Prestwick_661; 8-Methoxypsoralen with ultraviolet A therapy; 9-methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; BPBio1_000680; 9-METHOXY-7H-FURO[3,2-G][1]BENZOPYRAN-7-ONE; IDI1_000763; D00139; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; Spectrum4_000052; CCRIS 2083; Meloxine; Prestwick2_000479; BSPBio_001997; Methoxsalen (JP15/USP); Geroxalen; KBio2_001503; NSC45923; Ammodin; 8-MP; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; KBioGR_000543; Methoxsalen, 8-; 8-Methoxy-2',3',6,7-furocoumarin; AIDS-001590; ACon1_000174; Puvalen; Oxsoralen (TN); DivK1c_000763; Ammoidin; 8-Methoxypsoralen; Meladinin; NCI60_004085; 8-Methoxy(furano-3'.2':6.7-coumarin); SPBio_001004; Oxsoralen-Ultra; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; SPECTRUM1500400; 298-81-7; Spectrum5_001891; Xanthotoxin; 7H-Furo(3,2-g)(1)benzopyran-7-one, 9-methoxy-; Spectrum3_000499; 9-methoxy-7-furo[3,2-g]chromenone; NCGC00016418-01; KBio2_006639; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; M3501_SIAL; New-Meladinin; Oxsoralen Lotion; 10-32-2; 8-Methoxy-[furano-3'.2':6.7-coumarin]; A1783/0075596; KBio1_000763; |
C12H8O4 |
216.19 |
COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 |